Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a correction to a previous announcement made on January 5, 2011, regarding an administrative error in the details of changes in directors' interests in the company's Ordinary shares and American Depository Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a notification of director share transactions and does not contain financial performance data.
Material Changes
The material change reported is the correction of previously stated details regarding the allocation of share awards to Non-Executive Directors. The corrected data reflects the provisional allocation of awards on December 31, 2010, resulting from the annual reinvestment of dividends paid throughout 2010.
Management Commentary and Risks
Management commentary is limited to the explanation of the administrative error and the provision of corrected transaction details. No specific risks, contingencies, or unusual items regarding the company's operations or financial outlook are discussed in this filing.
Important Facts for Investors
- The filing corrects an error in the January 5, 2011 announcement concerning Non-Executive Director share holdings.
- Allocations were made on December 31, 2010, via dividend reinvestment for the 2010 fiscal year.
- Corrected average prices were £12.55 for Ordinary Shares and $39.18 for ADSs.
- Specific share counts were updated for directors including Sir Christopher Gent, Prof Sir Roy Anderson, Dr Stephanie Burns, Mr Lawrence Culp, Sir Crispin Davis, Sir Deryck Maughan, Mr James Murdoch, Dr Daniel Podolsky, Mr Tom de Swaan, and Sir Robert Wilson.
- The notification complies with Disclosure and Transparency Rule 3.1.4R(1)(a).